Incidental detection by [11C]choline PET/CT of meningiomas in prostate cancer patients

F. Fallanca, G. Giovacchini, M. Picchio, V. Bettinardi, C. Messa, F. Fazio

Research output: Contribution to journalArticlepeer-review


Aim. Anti-androgenic hormonal therapy in prostate cancer patients with concomitant meningioma may result in tumor growth and development of neurological symptoms. Positron emission tomography/computed tomography (PET/CT) with [11C]choline is used for restaging prostate cancer patients with biochemical failure. In vitro and in vivo data support altered choline metabolism in meningiomas. Methods. During a retrospective study in prostate cancer patients witii biochemical failure referred to our institution between November 2004 and Ja-nuary 2007, encephalic focal uptake of [ 11C]choline was incidentally noted in 4 patients, 2 of which had been taking luteinizing hormone-releasing hormone analogs. Results. Subsequent to the incidental finding, one patient underwent surgical removal of the meningioma; strict neuroradiological follow-up was planned for the 3 other patients. Conclusion. We suggest that in prostate cancer patients candidate for anti-androgenic therapy the whole body [11C]choline PET/CT scan should include the whole skull to check for the possible presence of meningiomas. This could help to identify patients at risk for the development of neurological symptoms during anti-androgenic therapy and help the referring urologist in the clinical management of these patients.

Original languageEnglish
Pages (from-to)417-421
Number of pages5
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Issue number4
Publication statusPublished - Aug 2009


  • Choline
  • Computed tomography
  • Gonadotropin-releasing hormone, agonists and inhibitors
  • Meningioma
  • Prostatic neoplasms
  • Tomography, emission computed

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Incidental detection by [11C]choline PET/CT of meningiomas in prostate cancer patients'. Together they form a unique fingerprint.

Cite this